ArticleInternational journal of clinical and experimental pathology2018
Targeting STAT3 induces apoptosis and suppresses cell growth and invasion by inactivation of Slug signaling in retinoblastoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2021-12-15Error in Analyses · Error in Results and/or Conclusions · Results Not Reproducible ·
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAbnormalities in the STAT3 pathway are involved in the oncogenesis of several cancers. However, the mechanism by which dysregulated STAT3 signaling inhibited the progression of human retinoblastoma (RB) has not been elucidated. To investigate the role of targeting STAT3 in RB progression, we inhibited STAT3 with Y79 cells and depleted STAT3 with a siRNA.
resultsOur results demonstrate that targeting STAT3 inhibited survival and induced apoptosis of Y79 cells through downregulation of Slug and upregulation of PUMA. In addition, targeting STAT3 inhibited invasion and migration of Y79 cells through downregulation of Slug and upregulation of E-cadherin. Furthermore, Slug overexpression inhibited PUMA and E-cadherin upregulation in the Y79 cells with targeting STAT3. Targeting PUMA and E-cadherin reversed the role of targeting STAT3 in the Y79 cells.
conclusionsour findings showed that targeting STAT3 inhibited survival, invasion, and migration in Y79 cells through inactivation of Slug, resulting in the upregulation of PUMA and E-cadherin, and provide novel evidence that the STAT3/Slug pathway may be a new potential target for therapy of RB.
Indexed as
Identifiers
31938117PMC6957960W3008702918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.